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G rowth monitoring of apparently healthy children aims at early detection of serious conditions (1) . This monitoring combines clinical expertise and the use of algorithms defining abnormal growth (1) . Substantial empirical evidence shows that the actual practice of growth monitoring is suboptimal worldwide, with long diagnostic delays for target conditions as severe as GH deficiency (GHD), Turner syndrome, celiac disease, Crohn disease, hypothalamic-optochiasmatic tumors, and chronic kidney disease (2) (3) (4) , and large numbers of futile referrals for children with normal variants of growth (5) (6) (7) . We have shown that the main cause of this suboptimal monitoring is the lack of standardization of primary care physician practice with validated tools (8, 9) .
Seven algorithms have been proposed to define abnormal growth (Supplemental Table 1 ) (10) . Some are based on straightforward unique thresholds and others on more complex combinations of auxological parameters (see example in Supplemental Fig. 1 ). In a recent systematic review, the Grote and Saari clinical decision rules seemed the most promising, with high specificity (.96%) and acceptable sensitivity (.60%) in derivation samples (10) . However, the level of validation of these algorithms is low and limits their potential implementation in daily practice (10) . Furthermore, although these algorithms often provide contradictory indications about the abnormality of the growth of a given child, all available algorithms have never been compared head to head in terms of diagnostic performance.
External validation studies and head-to-head comparisons must take into account the international growth charts published by the World Health Organization (WHO) in 2006 (11, 12) . We and others have shown that for some countries, the distribution of height, weight, and body mass index (BMI) of contemporary children was closer to WHO growth charts than national references of their own country, except for the first 6 months of age (10, 13) . Nevertheless, the potential impact of the growth charts used on the performance of algorithms to define abnormal growth has been investigated in only two studies, performed in Finland and the United States, showing higher sensitivity of national than WHO growth charts for detecting cystic fibrosis and Turner syndrome, with lower specificity (14, 15) .
To improve growth-monitoring practices in the primary care setting by providing more validated and accurate tools, we performed, to our knowledge, the first external validation study with a head-to-head comparison of all existing algorithms and studied the potential impact of the use of WHO vs national French growth charts on their performance.
Population and Methods

Study design
We used a case-referent approach by applying the seven existing algorithms to growth data for children with priority target conditions of growth monitoring (cases) and apparently healthy children from the general population (referents). Such design is usually used and recommended to evaluate growthmonitoring algorithms given the low incidence of priority target conditions (2, 3, 10, (16) (17) (18) (19) . Among the numerous diseases that can affect child growth (20) , we a priori selected three conditions [Turner syndrome, GHD related to pituitary stalk interruption syndrome (GHD-PSIS), including isolated ectopic posthypophysis, and celiac disease] because they were frequently studied during the derivation and validation of algorithms (3, 17, 19) and because they ranked in top positions of a recent transdisciplinary consensus on priority target conditions of growth monitoring (21) .
This study is reported according to the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement (Supplemental Table 2 ) (22) . It was approved by the Necker-Enfants Malades ethics committee (in May 2015) and the National Commission for Data Protection (no. 1841989 in April 2016). In accordance with French law, parents and older children were informed of the use of routinely collected medical data and asked whether they were opposed to this use.
Setting and participants
Cases were children followed in the departments of pediatric endocrinology and pediatric gastroenterology of Robert-Debré, Fondation Rothschild, and Necker-Enfants Malades hospitals in Paris and born between 1989 and 2014. Turner syndrome was diagnosed by karyotype (X0 or mosaic). GHD-PSIS was diagnosed by IGF-1 level, GH simulation tests, and MRI. Celiac disease was diagnosed by immunoglobulin A antitissue transglutaminase serology plus confirmation by endoscopy and duodenal biopsy. We excluded Turner syndrome and GHD-PSIS cases with antenatal diagnosis. Additional exclusion criteria were applied to appropriately analyze theoretical reductions in time to diagnosis provided by algorithms by comparison with daily practices (see below): diagnosis in the neonatal period (e.g., based on hypoglycemia or midline malformations related to GHD, or lymphedema or cardiac malformations related to Turner syndrome), household outside France before the date of diagnosis, second case or more among siblings, and fortuitous discovery (e.g., an autoimmunity workup leading to the discovery of celiac disease in a patient with type 1 diabetes).
Referents were contemporary French children recruited in three studies already described in detail (23) (24) (25) (25) . We assumed that the children who participated in these three studies were healthy and notably not affected by any of the three target conditions studied because they were regularly followed up and because the incidence of these conditions is very low in the general population (e.g., incidence range for celiac disease: 10 to 17.4 per 100,000) (26) (27) (28) (29) (30) (31) .
Auxological parameters
Demographic, growth, and clinical data for cases were extracted from medical records of children. The auxological and clinical parameters needed to apply the seven algorithms are detailed in Supplemental Table 1 (10) . Absolute height, weight, and BMI were converted to a standard deviation score according to the WHO or national growth charts (11, 12, 32) . Distance to standardized target height was calculated with the Tanner target height equation (33) . As with others (16, 34), we adapted some of the algorithms because the authors provided insufficient details or because some parameters used in algorithms (mainly clinical signs) were not available for case series and referent populations (Supplemental Tables 1 and 3 ).
Statistical analysis
We described data for case series and referent populations. Then, we applied the seven algorithms to the growth data for case series and referent populations to assess their performance by calculating specificity (percentage of referents not considered to have abnormal growth) and sensitivity (percentage of cases considered to have abnormal growth before the age at diagnosis) as well as 95% CIs by using the exact binomial method. We also calculated the median [interquartile range (IQR)] theoretical reductions in time to diagnosis as the difference between the real age at diagnosis for cases and the age at which the algorithm became positive (as illustrated in Fig. 1 ). We arbitrarily set a value of zero for the theoretical reduction in time to diagnosis for children not identified as having disease by the algorithm before the real age at diagnosis. The performance of algorithms was studied by available growth data for children without using interpolation methods to avoid overestimating the performance in terms of the real frequency of measurement in daily practice.
We tried to identify the "best" algorithm for growth monitoring. Growth-monitoring algorithms are population-based, repeated, early-detection tests that must be highly specific (35) . Thus, we first selected algorithms with specificity greater than 98%. This value corresponds to a maximum of 2% false-negative results that the health care system can support, as suggested by previous studies (3, 17, 19) . Among algorithms with high specificity, we compared their sensitivity by using the McNemar test for pairs (with continuity correction, if needed). The same test was used to compare the performance of algorithms according to the growth charts used, WHO or French national ones. We compared the theoretical reduction in time to diagnosis offered by each algorithm by using a stratified Cox model as appropriate for paired censored data, with the WHO and then national growth charts. The proportional hazards assumption was checked by testing the interaction with time and the normal distribution of martingale residuals. All analyses involved use of SAS version 9.4 (SAS Institute, Cary, NC).
Post hoc power calculation
All available data were used to maximize the power and generalizability of the results. A posteriori analysis revealed a statistical power estimation greater than 94% with an a level of 5% for an algorithm detecting a clinically meaningful theoretical reduction in time to diagnosis of 6 months or more (standard deviation of time to diagnosis ranging from 0.5 to 1.2 years).
Results
Characteristics of participants
Our Fig. 2 ). For apparently healthy children, the mean standardized height and weight was closer to WHO than national growth charts, as illustrated by z scores closer to 0 ( Table 1) .
Performance of algorithms
The specificity of algorithms ranged from 47.4% to 100% and from 44.8% to 100% with the WHO and national growth charts, respectively (Table 2) . Sensitivity ranged from 0% to 85.7% and from 0% to 87.5% depending on the target disease studied and the use of WHO and national growth charts, respectively ( Table 2) .
Two of the seven algorithms had specificity greater than 98% with national growth charts (Table 2) : the Grote clinical decision rules (99.3%) and the Coventry consensus (100%). One other algorithm had specificity close to 98%: the WHO criterion (93.2%). According to national growth charts, the Grote clinical decision rule had higher sensitivity than the Coventry consensus for children with GHD-PSIS (44.2% vs 6.1%, P , 0.0001), Turner syndrome (40.2% vs 8%, P , 0.0001), and celiac disease (4.6% vs 0%, P = 0.25) ( Table 2) . Similar results in comparing the sensitivity of the Grote clinical decision rule and the Coventry consensus were obtained with WHO growth charts ( Table 2) . None of these algorithms provided any statistically significant theoretical reduction in time to diagnosis, regardless of the growth chart used ( Table 3 ).
The sensitivity of the Grote clinical decision rule for GHD-PSIS was greater with the WHO than national growth charts (54% vs 44.2%, P , 0.0001) ( Table 2) . Also, the median theoretical reduction in time to diagnosis was greater with the WHO than national growth Figure 1 . Calculation of theoretical reduction in time to diagnosis according to WHO criteria (standardized height ,-2 SD) by using growth data for a child with GHD-PSIS diagnosed at age 5 y. charts (0.3 vs 0 years, P , 0.0001) ( Table 3) ; similar results were found for children with Turner syndrome (0.9 vs 0 years). The median theoretical reduction in time to diagnosis was null for children with celiac disease, regardless of the growth chart used ( Table 3 ). The negative likelihood ratios of the Grote clinical rule were 0.5 and 0.6 for GHD-PSIS, 0.5 and 0.6 for Turner syndrome, and 0.9 and 1.0 for celiac disease with WHO and national growth charts, respectively. The positive likelihood ratios were 33.8 and 63.1 for GHD-PSIS, 32.4 and 57.4 for Turner syndrome, and 4.8 and 6.6 for celiac disease, respectively.
Discussion
Main results and implication for practice
This first external validation study and head-to-head comparison of all algorithms proposed for growth monitoring provide a further level of evidence to guide their clinical implementation. Our results do not support the daily use of most algorithms because of poor specificity (WHO criterion, Dutch consensus, GHRS criteria, and Saari clinical decision rules) and/or sensitivity (Coventry consensus). These results agree with some previous preliminary reports of the apparent performance or external validity of these algorithms (2, 3, 10, (16) (17) (18) (19) 34) . However, other studies reported more encouraging results regarding sensitivity and/or specificity for Saari clinical decision rules (sensitivity of 97% for Turner syndrome and specificity of .95% for both rules); such differences may be explained by the overoptimism induced when developing clinical predictive models without external validation. We identified the Grote clinical decision rule as having the best performance. This rule was proposed in 2007 by a Dutch team after an in-depth mathematical analysis of growth charts of children with Turner syndrome (n = 777), cystic fibrosis (n = 216), GHD (n = 7), or celiac disease (n=120). The objective of this team was to replace a previous algorithm based on a national consensus of experts without analysis of individual patient data that was found to have a very low specificity (10) with a new highly specific one (.98%). Initial performance was assessed, but no internal validation was performed. Our external validation study involving data from patients with different conditions and diagnostic criteria and recruited in another country is quite concordant with previous reports: sensitivity of 4.6% to 54% vs 27% to 85% and specificity of 98% to 99% vs 98% to 99%. Although being the "best" algorithm, the Grote clinical decision rule is potentially limited by the short reduction in time to diagnosis (0.9 or 0 years with WHO or national growth charts, respectively) that it offered among tested children. Thus, refinement of this rule may be required to optimize its performance. Interestingly, Grote et al. (17) did not use growth velocity in their algorithm. This parameter could be added in a future refined algorithm given that this criterion seems to be very effective to detect early GHD and Turner syndrome, for example (2) . The Grote clinical decision rule reached level II validation according to the EvidenceBased Medicine Working Group scale and could be used in various settings with confidence in its accuracy (41) . Of note, this rule was not cited in one survey of growthmonitoring practices of primary care physicians in Europe in 2012 (8) , nor in a more recent survey of definitions of abnormal growth taught during the medical curricula in 33 European countries (9) . The use of this algorithm by primary care physicians in daily practice could be limited by its complexity; however, we showed in 2013 that many European primary care pediatricians declared using a software to monitor growth (61% in Europe) (8), a level that has probably increased since then. Use of such an algorithm in the form of a software-assisted medicine component should be feasible in daily practice.
Use of WHO growth charts to apply the Grote clinical decision rule would have led to higher sensitivity (about 10 percentage points) but lower specificity (1 percentage point, from 99.3% to 98.4%) than with national growth charts. Such a change in specificity could seem not clinically relevant, but can be illustrated with an example: among 800,000 children born the same year in France, 19,200 would have been inappropriately considered to have abnormal growth and potentially referred for diagnostic workup with related unnecessary anxiety and health costs. Thus, depending on their clinical constraints, primary care physicians could choose to use WHO growth charts for higher sensitivity or national growth charts for higher specificity.
The choice of a high threshold (98%) used to identify the best algorithm is supported by the nature of growth monitoring, representing a continuous process from birth to adulthood, with an algorithm aiming at completing clinical experience, not replacing it. A lower threshold could be acceptable with sequential algorithms, with patients not directly referred for diagnostic workup but rather placed under scrutiny.
Strengths and limitations
The limitations of our study include cases obtained from only three hospital departments in one region of France. It is difficult to anticipate the impact of this potential recruitment bias on our results concerning the sensitivity and theoretical reduction in time to diagnosis. However, the median age at diagnosis was similar to that reported in the literature based on single-center as well as multicenter recruitment: 38 vs 43 months for GHD-PSIS and 100 vs 120 months for Turner syndrome. For celiac disease, the median age at diagnosis was shorter than that reported in the literature (80 months) and could explain the poor performance of the algorithm both in sensitivity and theoretical reduction in time to diagnosis. Our study was based on a smaller sample size of children (n = 112 for Turner syndrome and 66 for celiac disease) as compared with other validation studies of single algorithms (n = 124 to 777 for Turner syndrome and 120 to 177 for celiac disease) (3, 17, 19) . However, the phenotype of our patients was better established than in these studies. Indeed, we included children with certitude markers of diagnosis (e.g., PSIS for GHD). We also applied stringent inclusion criteria for calculating theoretical reduction in time to diagnosis. The performance of algorithms was evaluated with only three priority target conditions, with associated abnormal growth patterns that may differ from those of other conditions. For example, growth patterns of children affected by craniopharyngioma usually associate height deflection and weight increase (4) . Such a specific pattern may lead to a different evaluation of algorithm performance. The recent consensus on priority target conditions for algorithms for monitoring children's growth will help in conducting a next validation step that will use data of children affected by all these priority target conditions (21) . Some criteria used in some algorithms, including "dysmorphic features," "disproportion," "emotional deprivation," or "pubertal signs," were not available in our case series or referent populations (17, 39) , which may have affected their performance by underestimating their sensitivity. However, these parameters were not well defined in algorithms and are difficult to integrate in validation studies, as acknowledged by the authors of the algorithms themselves (16, 34) . Thus, we assumed that these very rare features were normal, as did the authors of the algorithms in their own validation studies (16, 34) . Finally, as others (3, 17, 19) , we assumed that the number of cases not yet diagnosed in referents was low and would thus result in a slight overestimation of the number of false positive.
As compared with other external validation studies, we used advanced statistical methods for comparing the theoretical reduction in time to diagnosis. We took into account right censoring, which occurs when a case is considered to show abnormal growth after the age at diagnosis.
Conclusion
Among the seven algorithms proposed for defining abnormal growth, the Grote clinical decision rule had the best performance, with specificity greater than 98% and sensitivity from 42% to 54% depending on the studied target conditions. Sensitivity was higher with the WHO than national growth charts at the expense of specificity. The transportability of our results in terms of sensitivity should be further analyzed for children with other targeted diseases of growth monitoring, such as Crohn disease and craniopharyngioma. Nonetheless, the sensitivity of the Grote clinical decision rule remains low, with limited potential for theoretical reduction in time to diagnosis. Studies are needed to obtain better algorithms for improving this sensitivity without losing too much specificity.
